The purpose of the study is to register the occurrence of cardiovascular disease among type 2 diabetes patients across ten countries across the world. Participants will be asked to give information about their health. Participants will continue their normal way of life and will not get any medication other than prescribed to them by their doctor. Participants' participation will be one day/one visit at their doctor. The study will last for about 6 months in total.

Inclusion Criteria:

• Signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol)
• Male or female, age more than or equal to 18 years at the time of signing informed consent (in Algeria more than or equal to 19 years; in Japan more than or equal to 20 years).
• Diagnosed with T2DM more than or equal to 180 days prior to the day of signing the informed consent

Exclusion Criteria:

• Previous participation in this study. Participation is defined as having given informed consent in this study
• Diagnosed with Type 1 diabetes
• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
• Patients with known congenital heart disease/malformation

The study population will consist of male and female adults diagnosed with T2DM.

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com